Ep38: Harlan and Chad Robins (Take 2)
The co-founders of Adaptive Biotechnologies on immune sequencing.
Chief Executive Officer, Adaptive Biotechnologies
Search every verified Chad Robins interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Chad Robins, CEO of Adaptive Biotechnologies, discussed the company's work in immune sequencing during a February 2019 podcast appearance. He described the firm's focus on sequencing T-cell and B-cell receptors, emphasizing that the resulting data is both quantitative and contains detailed sequence information due to the biophysical nature of immune interactions. Robins noted that the company made a strategic bet on developing cancer-specific T-cell receptors, positioning Adaptive as "the world's first monoclonal antibody company, but for T-cell receptors." Robins also addressed the company's recent partnership with Microsoft Research, aimed at creating a large-scale map of immune responses. He highlighted the potential clinical applications of tracking cancer clones in patients, such as monitoring for recurrence or avoiding overtreatment when a cancer clone is no longer present. He acknowledged that the clinical utility of such information requires further prospective studies, but expressed excitement about the rapid pace of learning in the field, particularly regarding autoimmune diseases, which he said affect millions of Americans and remain poorly understood due to a lack of prior tools for interrogation.
The co-founders of Adaptive Biotechnologies on immune sequencing.
In this condensed version of Shauna Swerland's conversation with Chad Robins from 2019, you'll hear the origin story of Adaptive Biotechnologies, the corporate culture Chad is building there, and what Chad sees as the most important tasks of a CEO. See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.
Chad Robins, CEO and Co-founder of Adaptive Biotechnologies, discusses their recent partnership with Microsoft to decode the immune system's response to CODVID-19 and develop better diagnostic tools and their partnership with Amgen to develop potential antibody therapies to treat the disease. Chad also shares how the medical field is adapting and facing new challenges during this pandemic. See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.
Chad Robins is the CEO of Adaptive Biotechnologies. His company, which he co-founded with his brother Harlan, has received over $400 million in funding as it drives ground-breaking research in cancer and other immune-mediated diseases. Chad simplifies his role as a CEO into three categories and breaks down this complex industry for everyone to understand. Listen to this riveting episode and hear how he moved from investment banking to biotech, what working with his brother is like and how 100 days spent in the wilderness is what influences his leadership style to this day. See omnystudio.com…
Chad Robins is the chief executive officer and co-founder of Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since its founding in 2009, Chad has led Adaptive in building a proprietary immune medicine platform that fuels businesses across life sciences research, clinical diagnostics, and drug discovery. In 2019, Chad guided the company through its initial public offering, which was one of the year’s most successful biotech IPOs. Under his le…
Adaptive Biotech's T cell test will help detect whether you've had Covid-19 before or not. The test just received FDA approval for emergency use. Chad Robins, Adaptive Biotechnologies co-founder and CEO, joins 'Closing Bell' to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to l…
Adaptive biotechnologies CEO Chad Robins says the company is working night and day to develop an effective antibody Covid-19 treatment. He says the company won't be first to provide antibody treatments, but once developed it will help many patients across the United States. He joins 'Closing Bell' to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC…
Chad Robins, Adaptive Biotechnologies co-founder and CEO, joins "Squawk Box" to discuss the company's research efforts to develop a Covid-19 vaccine as well as Russian President Vladimir Putin's announcement that the country has registered what it claims to be the first vaccine for coronavirus in the world. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC T…
The race is on for improved testing, treatment and a vaccine for Covid-19. One company is partnering with Microsoft to decode how the human immune system responds to the virus. Chad Robins, Adaptive Biotechnologies CEO and co-founder, joins "Squawk Box" to discuss ways to make testing more reliable. Microsoft and Adaptive Biotechnologies are working together to study how the human immune system responds to the COVID-19 coronavirus. By understanding the immune signature, meaning how humans are responding to the disease, the companies hope to speed the process of developing a more accurate di…
Adaptive Biotechnologies CEO Chad Robins, whose Seattle company completed one of the most spectacular IPOs of the year by raising $300 million in June, discusses the transformative technologies that may finally push the industry out of the pen-and-paper era in the Health Tech Track at the 2019 GeekWire Summit. Moderated by Luke Timmerman of The Timmerman Report.
Chad Robins, CEO and co-founder of Adaptive Biotechnologies, joins "Squawk Box" ahead of his company's IPO on the Nasdaq. The life sciences and clinical diagnostic company could become the biggest biotech listing of 2019.
Sign in to search the full transcript archive, filter by topic, and access every quote from Chad Robins.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans